Statistically the market is still 'expensive': Savita Subramanian

Bank of America Securities strategist Savita Subramanian discusses S&P 500 valuations, earnings revisions, and the consumer outlook. The piece is commentary rather than a new market catalyst, with no specific price targets, earnings figures, or policy changes cited. The content is broadly market-relevant but likely incremental for trading.

Analysis

The setup is less about headline valuation and more about dispersion: when index-level multiples look “full,” the opportunity shifts to balance-sheet quality, earnings revision breadth, and who can defend margins if the consumer slows. That usually favors quality large caps and cash-generative software/health care over cyclical beta, because passive flows keep rewarding index heaviness even as fundamental leadership narrows. The second-order effect is that weak revisions in the bottom half of the index can stay weak longer than expected, creating a prolonged underperformance regime for lower-quality cyclicals and small-cap domestic demand names.

The consumer piece matters most in the margin, not the top line. If household demand is still holding but becoming more selective, the winners are companies with pricing power, premium mix, and low promotional intensity; losers are retailers and brands that need discounting to maintain traffic. That dynamic tends to show up first in gross margin pressure 1-2 quarters before revenue deterioration, so the market often misprices the early phase by focusing on “resilient sales” while missing deteriorating profitability.

A key contrarian point: high index valuations do not automatically mean broad downside if earnings revisions are improving faster than rates are rising. In that case, the market can grind higher through a multiple ceiling via earnings compounding, but only if revisions breadth keeps expanding. If revisions narrow again, the downside is asymmetric because positioning is already crowded in a few mega-cap winners and there is limited fundamental support elsewhere.

Near term, the most important catalyst is the next revisions cycle and consumer commentary from bellwethers over the next 4-8 weeks. The risk to the bullish quality trade is a re-acceleration in rates that compresses long-duration equity multiples; the risk to the bearish consumer trade is an improving real wage backdrop that delays the demand rollover for another 1-2 quarters.

Key Decisions for Investors

• Long XLV vs short XRT over the next 1-3 months: health care offers better earnings durability while consumer discretionary remains exposed to promotional pressure; target 5-8% relative outperformance if revisions stay weak in retail.
• Add QQQ on pullbacks, but hedge with an equal notional short IWM for a 2-4 month pair: if the market remains concentrated, mega-cap quality should outperform small-cap cyclicals by 300-500 bps.
• Short basket of low-quality consumer names with margin risk, expressed via XRT or a targeted retail/brand basket, into earnings season: best risk/reward is where consensus still assumes stable gross margins despite softening traffic.
• Prefer long-duration quality over broad cyclicals: initiate/maintain longs in MSFT, COST, and V on weakness, with a 6-12 month horizon; these names can compound even if index multiples stay capped.
• Use SPY put spreads rather than outright shorts if entering now: valuation downside is likely to be shallow and choppy unless revisions roll over, so defined-risk protection is better than directional bearishness.